These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38632528)

  • 41. Systemic treatment options for non-small cell lung cancer after failure of previous immune checkpoint inhibitors: a bayesian network meta-analysis based on randomized controlled trials.
    Wang K; Fu Z; Sun G; Ran Y; Lv N; Wang E; Ding H
    BMC Immunol; 2024 Jun; 25(1):37. PubMed ID: 38937711
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and efficacy of restarting immune checkpoint inhibitors in non-small cell lung cancer patients following immune-related adverse events: a systematic review and meta-analysis.
    Tan K; Wang A; Zheng Y; Wang S; Wang C; Li J; Lu X; Dong H; Zheng J; Cui H
    Clin Transl Oncol; 2024 Jun; ():. PubMed ID: 38922538
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a meta-analysis based on mixed-effect models.
    Zheng J; Deng Y; Huang B; Chen X
    Front Med (Lausanne); 2023; 10():1198950. PubMed ID: 37583422
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk Factors for Immune Checkpoint Inhibitor-Related Pneumonitis in Cancer Patients: A Systemic Review and Meta-Analysis.
    Zhou P; Zhao X; Wang G
    Respiration; 2022; 101(11):1035-1050. PubMed ID: 36108598
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic relevance of prognostic nutritional indices in gastric or gastro-esophageal junction cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
    Hou S; Song D; Hao R; Li L; Zhang Y; Zhu J
    Front Immunol; 2024; 15():1382417. PubMed ID: 38966640
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis.
    Pei WG; Chen WZ; Wu YK; Tan SX; Jie ZG
    World J Gastrointest Oncol; 2023 Feb; 15(2):352-367. PubMed ID: 36908315
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pre-existing Autoimmune Diseases and Immune Checkpoint Inhibitors for Cancer Treatment: Considerations About Initiation, Flares, Immune-Related Adverse Events, and Cancer Progression.
    Sparks JA
    Rheum Dis Clin North Am; 2024 May; 50(2):147-159. PubMed ID: 38670718
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review.
    Yang K; Li J; Sun Z; Zhao L; Bai C
    Ther Adv Med Oncol; 2020; 12():1758835920975353. PubMed ID: 33294036
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Xie E; Yeo YH; Scheiner B; Zhang Y; Hiraoka A; Tantai X; Fessas P; de Castro T; D'Alessio A; Fulgenzi CAM; Xu S; Tsai HM; Kambhampati S; Wang W; Keenan BP; Gao X; Xing Z; Pinter M; Lin YJ; Guo Z; Vogel A; Tanaka T; Kuo HY; Kelley RK; Kudo M; Yang JD; Pinato DJ; Ji F
    JAMA Oncol; 2023 Oct; 9(10):1423-1431. PubMed ID: 37615958
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.
    Cappelli LC; Bingham CO
    Arthritis Rheumatol; 2021 Apr; 73(4):553-565. PubMed ID: 33186490
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rheumatic immune-related adverse events induced by immune checkpoint inhibitors.
    Zhong H; Zhou J; Xu D; Zeng X
    Asia Pac J Clin Oncol; 2021 Jun; 17(3):178-185. PubMed ID: 32717098
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis.
    Tian JC; Liu H; Yan LJ; Ding ZN; Han CL; Tian BW; Tan SY; Dong ZR; Wang DX; Xue JS; Mao XC; Yan YC; Li T
    Clin Exp Med; 2023 Oct; 23(6):2115-2129. PubMed ID: 36385419
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors in advanced lung cancer: A systematic review and meta-analysis.
    Zheng Y; Dong H; Yu Y; Hu Z; Xue C; Zhang X; Cui H
    Int Immunopharmacol; 2023 Oct; 123():110785. PubMed ID: 37598630
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis.
    Wu Z; Chen Q; Qu L; Li M; Wang L; Mir MC; Carbonara U; Pandolfo SD; Black PC; Paul AK; Di Lorenzo G; Porpiglia F; Mari A; Necchi A; Rouprêt M; Psutka SP; Autorino R
    Eur Urol; 2022 Apr; 81(4):414-425. PubMed ID: 35101302
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study.
    Martinez Chanza N; Xie W; Issa M; Dzimitrowicz H; Tripathi A; Beuselinck B; Lam E; Zakharia Y; Mckay R; Shah S; Mortazavi A; R Harrison M; Sideris S; Kaymakcalan MD; Abou Alaiwi S; Nassar AH; Nuzzo PV; Hamid A; K Choueiri T; C Harshman L
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217762
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis.
    Zou Y; Zou X; Zheng S; Tang H; Zhang L; Liu P; Xie X
    Ther Adv Med Oncol; 2020; 12():1758835920940928. PubMed ID: 32874208
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association between immune-related adverse events and the prognosis of patients with gastric cancer treated with nivolumab: a meta-analysis.
    Zhang YJ; Tian QY; Wang CE
    Front Oncol; 2024; 14():1408755. PubMed ID: 39301552
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
    Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
    BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
    Li Y; Liang X; Li H; Chen X
    Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.